Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes

Ki Hwan Kwon, Jin Young Oh, Young Soon Yoon, Yun Jeong Jeong, Kyung Soo Kim, Sung Joon Shin, Jae Woo Chung, Hee Jin Huh, Seok Lae Chae, Seong Yeon Park

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

Colistimethate sodium (CMS) is increasingly used to treat multidrug-resistant Gram-negative bacilli infections. However, the incidence of CMS-associated nephrotoxicity has not been evaluated in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia. This retrospective study included 120 patients with CRAB pneumonia treated with intravenous CMS for ≥72 h. The objective of the study was to determine risk factors for CMS-induced nephrotoxicity and 30-day mortality in patients with CRAB pneumonia. Of the 120 patients with CRAB pneumonia, 61 (51%) developed nephrotoxicity. Multivariate analysis showed that dose per ideal body weight (IBW) [odds ratio (OR) = 1.28, 95% confidence interval (CI) 1.01-1.62; P = 0.04], Charlson co-morbidity index (OR = 1.31, 95% CI 1.06-1.60; P = 0.01) and septic shock (OR = 3.16, 95% CI 1.32-7.60; P = 0.01) were associated with CMS-associated nephrotoxicity. Thirty-day mortality was 33% (39/120). Multivariate analysis showed that higher daily doses of CMS per IBW [hazard ratio (HR) = 0.81, 95% CI 0.67-0.98; P = 0.03] and longer duration of CMS therapy (HR = 0.86, 95% CI 0.79-0.95; P = 0.002) were associated with increased survival. Septic shock (HR = 3.91, 95% CI 1.95-7.83; P < 0.001) and corticosteroid use (HR = 3.49, 95% CI 1.67-7.28; P = 0.001) were associated with decreased survival in patients with CRAB pneumonia. Higher daily doses of CMS per IBW, Charlson comorbidity index and septic shock were significant risk factors for CMS-associated nephrotoxicity. However, CMS-associated nephrotoxicity does not appear to have an impact on mortality.

Original languageEnglish
Pages (from-to)605-609
Number of pages5
JournalInternational Journal of Antimicrobial Agents
Volume45
Issue number6
DOIs
StatePublished - 27 Nov 2015

Keywords

  • Carbapenem-resistant Acinetobacter baumannii
  • Colistimethate sodium
  • Nephrotoxicity
  • Pneumonia

Fingerprint

Dive into the research topics of 'Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes'. Together they form a unique fingerprint.

Cite this